Venetoclax-Navitoclax With Cladribine-based Salvage Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT ID: NCT06007911
Last Updated: 2024-08-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE1
INTERVENTIONAL
2024-08-31
2027-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
NCT04797767
Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome
NCT03404193
Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
NCT06177067
Efficacy and Pharmacogenomics of Cladribine Based Salvage Chemotherapy in Patients with Relapse/Refractory and Secondary Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS)
NCT03150004
BCL2i CLAG-M in R/R Acute Myeloid Leukemia
NCT06660368
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cladribine-Low Dose Cytarabine Backbone Dose Level -1
Dose level -1 will be considered only if there are dose-limiting toxicities at dose level 0. This is a regimen of navitoclax, venetoclax, cladribine and cytarabine.
Navitoclax Dose Level -1
25 mg by mouth on days 1-7.
Venetoclax Dose Level -1
400 mg by mouth on days 1-7.
Cladribine
5 mg/m\^2 intravenously days 1-5.
Cytarabine (Cladribine Low Dose Cytarabine Backbone)
20 mg/m\^2 subcutaneous days 1-10.
Cladribine-Low Dose Cytarabine Backbone Dose Level 0
This is a regimen of navitoclax, venetoclax, cladribine and cytarabine.
Navitoclax Dose Level 0
50 mg by mouth on days 1-10.
Venetoclax Dose Levels 0 to 2
400 mg by mouth on days 1-14.
Cladribine
5 mg/m\^2 intravenously days 1-5.
Cytarabine (Cladribine Low Dose Cytarabine Backbone)
20 mg/m\^2 subcutaneous days 1-10.
Cladribine-Low Dose Cytarabine Backbone Dose Level 1
This is a regimen of navitoclax, venetoclax, cladribine and cytarabine.
Navitoclax Dose Level 1
75 mg by mouth on days 1-10.
Venetoclax Dose Levels 0 to 2
400 mg by mouth on days 1-14.
Cladribine
5 mg/m\^2 intravenously days 1-5.
Cytarabine (Cladribine Low Dose Cytarabine Backbone)
20 mg/m\^2 subcutaneous days 1-10.
Cladribine-Low Dose Cytarabine Backbone Dose Level 2
This is a regimen of navitoclax, venetoclax, cladribine and cytarabine.
Navitoclax Dose Level 2
100 mg by mouth on days 1-10.
Venetoclax Dose Levels 0 to 2
400 mg by mouth on days 1-14.
Cladribine
5 mg/m\^2 intravenously days 1-5.
Cytarabine (Cladribine Low Dose Cytarabine Backbone)
20 mg/m\^2 subcutaneous days 1-10.
Cladribine-Low Dose Cytarabine Backbone Dose Maximum Tolerated Dose (MTD)
The MTD is the highest dose level at which no more than 1 of 6 treated participants, experiences a dose-limiting toxicity.
Navitoclax Dose Level -1
25 mg by mouth on days 1-7.
Navitoclax Dose Level 0
50 mg by mouth on days 1-10.
Navitoclax Dose Level 1
75 mg by mouth on days 1-10.
Navitoclax Dose Level 2
100 mg by mouth on days 1-10.
Venetoclax Dose Level -1
400 mg by mouth on days 1-7.
Venetoclax Dose Levels 0 to 2
400 mg by mouth on days 1-14.
Cladribine
5 mg/m\^2 intravenously days 1-5.
Cytarabine (Cladribine Low Dose Cytarabine Backbone)
20 mg/m\^2 subcutaneous days 1-10.
CLAG-M Backbone Level -1
Dose level -1 will be considered only if there are dose-limiting toxicities at dose level 0. This is a regimen of navitoclax, venetoclax, cladribine, cytarabine, mitoxantrone and G-CSF.
Navitoclax Dose Level -1
25 mg by mouth on days 1-7.
Venetoclax Dose Level -1
400 mg by mouth on days 1-7.
Cladribine
5 mg/m\^2 intravenously days 1-5.
Cytarabine (CLAG-M Backbone)
1.5 g/m\^2 intravenously days 1-5.
Mitoxantrone
10 mg/m\^2 intravenously days 1-3.
Granulocyte Colony-Stimulating Factor
300 mcg subcutaneously days 1-5.
CLAG-M Backbone Level 0
This is a regimen of navitoclax, venetoclax, cladribine, cytarabine, mitoxantrone and granulocyte colony-stimulating factor (G-CSF).
Navitoclax Dose Level 0
50 mg by mouth on days 1-10.
Venetoclax Dose Levels 0 to 2
400 mg by mouth on days 1-14.
Cladribine
5 mg/m\^2 intravenously days 1-5.
Cytarabine (CLAG-M Backbone)
1.5 g/m\^2 intravenously days 1-5.
Mitoxantrone
10 mg/m\^2 intravenously days 1-3.
Granulocyte Colony-Stimulating Factor
300 mcg subcutaneously days 1-5.
CLAG-M Backbone Level 1
This is a regimen of navitoclax, venetoclax, cladribine, cytarabine, mitoxantrone and G-CSF.
Navitoclax Dose Level 1
75 mg by mouth on days 1-10.
Venetoclax Dose Levels 0 to 2
400 mg by mouth on days 1-14.
Cladribine
5 mg/m\^2 intravenously days 1-5.
Cytarabine (CLAG-M Backbone)
1.5 g/m\^2 intravenously days 1-5.
Mitoxantrone
10 mg/m\^2 intravenously days 1-3.
Granulocyte Colony-Stimulating Factor
300 mcg subcutaneously days 1-5.
CLAG-M Backbone Level 2
This is a regimen of navitoclax, venetoclax, cladribine, cytarabine, mitoxantrone and G-CSF.
Navitoclax Dose Level 2
100 mg by mouth on days 1-10.
Venetoclax Dose Levels 0 to 2
400 mg by mouth on days 1-14.
Cladribine
5 mg/m\^2 intravenously days 1-5.
Cytarabine (CLAG-M Backbone)
1.5 g/m\^2 intravenously days 1-5.
Mitoxantrone
10 mg/m\^2 intravenously days 1-3.
Granulocyte Colony-Stimulating Factor
300 mcg subcutaneously days 1-5.
CLAG-M Backbone Maximum Tolerated Dose
The MTD is the highest dose level at which no more than 1 of 6 treated participants, experiences a dose-limiting toxicity.
Navitoclax Dose Level -1
25 mg by mouth on days 1-7.
Navitoclax Dose Level 0
50 mg by mouth on days 1-10.
Navitoclax Dose Level 1
75 mg by mouth on days 1-10.
Navitoclax Dose Level 2
100 mg by mouth on days 1-10.
Venetoclax Dose Level -1
400 mg by mouth on days 1-7.
Venetoclax Dose Levels 0 to 2
400 mg by mouth on days 1-14.
Cladribine
5 mg/m\^2 intravenously days 1-5.
Cytarabine (CLAG-M Backbone)
1.5 g/m\^2 intravenously days 1-5.
Mitoxantrone
10 mg/m\^2 intravenously days 1-3.
Granulocyte Colony-Stimulating Factor
300 mcg subcutaneously days 1-5.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Navitoclax Dose Level -1
25 mg by mouth on days 1-7.
Navitoclax Dose Level 0
50 mg by mouth on days 1-10.
Navitoclax Dose Level 1
75 mg by mouth on days 1-10.
Navitoclax Dose Level 2
100 mg by mouth on days 1-10.
Venetoclax Dose Level -1
400 mg by mouth on days 1-7.
Venetoclax Dose Levels 0 to 2
400 mg by mouth on days 1-14.
Cladribine
5 mg/m\^2 intravenously days 1-5.
Cytarabine (Cladribine Low Dose Cytarabine Backbone)
20 mg/m\^2 subcutaneous days 1-10.
Cytarabine (CLAG-M Backbone)
1.5 g/m\^2 intravenously days 1-5.
Mitoxantrone
10 mg/m\^2 intravenously days 1-3.
Granulocyte Colony-Stimulating Factor
300 mcg subcutaneously days 1-5.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients must have a diagnosis of morphologically documented AML or secondary AML from prior conditions, such as myelodysplastic syndrome (MDS), myeloproliferative neoplasm (MPN), MDS/MPN, chronic myelomonocytic leukemia (CMML) or therapy-related AML (t-AML), as defined by the World Health Organization (WHO) 2022 criteria.
3. Relapsed or refractory to at least one prior line of therapy.
4. Previous therapy with venetoclax.
5. Eastern Cooperative Oncology Group (ECOG) performance status of:
1. 0-3 for Arm A (i.e., Cladribine-low dose cytarabine backbone arm).
2. 0-2 for Arm B (i.e., CLAG-M backbone arm).
6. Left ventricular ejection fraction (LVEF) of:
1. LVEF ≥35% for Arm A (i.e., Cladribine-low dose cytarabine backbone arm).
2. LVEF ≥45% for Arm B (i.e., CLAG-M backbone arm).
7. Creatinine clearance (CrCl) as calculated by the Cockroft-Gault formula, of:
1. CrCl ≥ 30 mL/min for Arm A (i.e., Cladribine-low dose cytarabine backbone arm).
2. CrCl ≥ 40 mL/min for Arm B (i.e., CLAG-M backbone arm).
8. Clinical laboratory values within the following parameters:
1. Total bilirubin ≤ 1.5 × institutional upper limit of normal (ULN) unless attributable to underlying leukemia. Patient with total bilirubin \> 1.5 × institutional ULN may enroll if direct bilirubin ≤ 1.5 × institutional ULN of the direct bilirubin.
2. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3 × institutional ULN, unless attributable to underlying leukemia.
3. White blood cell (WBC) count \< 25,000/µL before Cycle 1, Day 1 of therapy (Note: Hydroxyurea, cytarabine or leukapheresis may be used to meet this criterion.)
4. Platelet count of at least 20,000/µL before Cycle 1, Day 1 of therapy (Note: Platelet transfusion can be used to meet this criterion.)
9. Female subjects who:
1. Are postmenopausal for at least one year before the screening visit, OR
2. Are surgically sterile, OR
3. If they are of childbearing potential:
i. Agree to practice one highly effective method and one additional effective (barrier) method of contraception, at the same time, from the time of signing the informed consent through four months after the last dose of study drug (female and male condoms should not be used together), OR ii. Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject. (periodic abstinence \[e.g., calendar, ovulation, symptothermal, post-ovulation methods\], withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception).
10. Male subjects, even if surgically sterilized (i.e., status post vasectomy), who:
1. Agree to practice effective barrier contraception during the entire study treatment period from the time of signing the informed consent through and through four months after the last dose of study drug (female and male condoms should not be used together), OR
2. Agree to practice true abstinence, when this is in line with the preferred and usual lifestyle of the subject. (periodic abstinence \[e.g., calendar, ovulation, symptothermal, post-ovulation methods for the female partner\] withdrawal, spermicides only, and lactational amenorrhea are not acceptable methods of contraception.)
11. Ability to understand a written informed consent document, and the willingness to sign it.
Exclusion Criteria
2. Prior therapy with B-cell lymphoma-extra large (BCL-XL) inhibitor.
3. Treatment with systemic antineoplastic therapy within 14 days or five half-lives from the last dose - whichever is longer - before Cycle 1, Day 1 of therapy. Radiation within 14 days before Cycle 1, Day 1 of therapy. The use of hydroxyurea/cytarabine for leukoreduction is permitted.
4. Hematopoietic stem cell transplantation (HCT) or chimeric antigen receptor T-cell therapy (CAR-T cell) within 60 days of enrollment. (If patients had prior allogeneic HCT, they should have no active graft-versus-host disease and should be off calcineurin inhibitors at least four weeks prior to cycle 1 day 1 of therapy.)
5. Current systemic treatment with strong or moderate Cytochrome P4503A (CYP3A) inducers within 7 days prior to Cycle 1, Day 1 of therapy.
6. Presence of another active malignancy requiring systemic treatment within the last 12 months, except for localized cancers that have been adequately treated.
7. Known HIV positive patients who DO NOT meet the following criteria:
1. Cluster of differentiation (CD) 4 count \> 350 cells/mm\^3.
2. Undetectable viral load.
3. Maintained on modern therapeutic regimens utilizing non-CYP-interactive agents.
4. No history of AIDS-defining opportunistic infections.
8. Known hepatitis B surface antigen seropositive or active hepatitis C infection. Note: Patients who have isolated positive hepatitis B core antibody (i.e., in the setting of negative hepatitis B surface antigen and negative hepatitis B surface antibody) must have an undetectable hepatitis B viral load. Patients who have positive hepatitis C antibody may be included if they have an undetectable hepatitis C viral load.
9. Female subjects who are both lactating and breastfeeding or of childbearing potential who have a positive serum test during screening.
10. Female subjects who intend to donate eggs (ova) during the course of the study or four months after receiving their last dose of the study drug(s).
11. Male subjects who intend to donate sperm during the course of this study or four months after receiving their last dose of the study drug(s).
12. Has consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges) or star fruit from three days prior to Cycle 1, Day 1 to throughout the study treatment.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical College of Wisconsin
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Guru Subramanian Guru Murthy
Assistant Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Guru Subramanian Guru Murthy, MD, MS
Role: PRINCIPAL_INVESTIGATOR
Medical College of Wisconsin
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Froedtert Hospital & the Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PRO00050186
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.